Back to discover

Protein / target

Alpha-ketoglutarate-dependent dioxygenase FTO

Encoded byFTOQ9C0B1Homo sapiensSwiss-Prot
Clinical-stage
Therapeutic maturity
1
Clinical candidates
Small-molecule tractable
Druggability
Advanced Clinical
3
Research papers

Protein at a glance

Biological role

Broad specificity oxidative DNA demethylase

Strongest disease association

Diabetes Mellitus, Type 2

Via encoding gene FTO · Genetic evidence · score 0.97

Therapeutic position

Clinically advancing target

Small molecules

Research activity

Emerging research

3 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

RNA demethylase that mediates oxidative demethylation of different RNA species, such as mRNAs, tRNAs and snRNAs, and acts as a regulator of fat mass, adipogenesis and energy homeostasis.

View complete UniProt function annotation

RNA demethylase that mediates oxidative demethylation of different RNA species, such as mRNAs, tRNAs and snRNAs, and acts as a regulator of fat mass, adipogenesis and energy homeostasis (PubMed:22002720, PubMed:25452335, PubMed:26457839, PubMed:26458103, PubMed:28002401, PubMed:30197295). Specifically demethylates N(6)-methyladenosine (m6A) RNA, the most prevalent internal modification of messenger RNA (mRNA) in higher eukaryotes (PubMed:22002720, PubMed:25452335, PubMed:26457839, PubMed:26458103, PubMed:30197295). M6A demethylation by FTO affects mRNA expression and stability (PubMed:30197295). Also able to demethylate m6A in U6 small nuclear RNA (snRNA) (PubMed:30197295). Mediates demethylation of N(6),2'-O-dimethyladenosine cap (m6A(m)), by demethylating the N(6)-methyladenosine at the second transcribed position of mRNAs and U6 snRNA (PubMed:28002401, PubMed:30197295). Demethylation of m6A(m) in the 5'-cap by FTO affects mRNA stability by promoting susceptibility to decapping (PubMed:28002401). Also acts as a tRNA demethylase by removing N(1)-methyladenine from various tRNAs (PubMed:30197295). Has no activity towards 1-methylguanine (PubMed:20376003). Has no detectable activity towards double-stranded DNA (PubMed:20376003). Also able to repair alkylated DNA and RNA by oxidative demethylation: demethylates single-stranded RNA containing 3-methyluracil, single-stranded DNA containing 3-methylthymine and has low demethylase activity towards single-stranded DNA containing 1-methyladenine or 3-methylcytosine (PubMed:18775698, PubMed:20376003). Ability to repair alkylated DNA and RNA is however unsure in vivo (PubMed:18775698, PubMed:20376003). Involved in the regulation of fat mass, adipogenesis and body weight, thereby contributing to the regulation of body size and body fat accumulation (PubMed:18775698, PubMed:20376003). Involved in the regulation of thermogenesis and the control of adipocyte differentiation into brown or white fat cells (PubMed:26287746). Regulates activity of the dopaminergic midbrain circuitry via its ability to demethylate m6A in mRNAs (By similarity). Plays an oncogenic role in a number of acute myeloid leukemias by enhancing leukemic oncogene-mediated cell transformation: acts by mediating m6A demethylation of target transcripts such as MYC, CEBPA, ASB2 and RARA, leading to promote their expression (PubMed:28017614, PubMed:29249359)

Subcellular location

NucleusNucleus speckleCytoplasm
Domains and Gene Ontology detail (22)

Gene Ontology

  • Ccytoplasm
  • Ccytosol
  • Cnuclear speck
  • Cnucleoplasm
  • Cnucleus
  • Fbroad specificity oxidative DNA demethylase activity
  • Fferrous iron binding
  • FmRNA N6-methyladenosine dioxygenase activity
  • Foxidative RNA demethylase activity
  • Ftransferase activity
  • FtRNA demethylase activity
  • Padipose tissue development

505 aa · 58 kDa · 4 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Oncogenic signallingUniProtImmune signallingUniProt · GO
View supporting evidence

Oncogenic signalling

  • ·RNA demethylase that mediates oxidative demethylation of different RNA species, such as…

Immune signalling

  • ·RNA demethylase that mediates oxidative demethylation of different RNA species, such as…
  • ·regulation of brown fat cell differentiation
  • ·regulation of white fat cell proliferation

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene FTO

Gene-level evidence surfaced through the gene FTOthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Diabetes Mellitus, Type 2
0.98Well supported

Genetic evidence dominant · Open Targets 0.62

Diabetes Mellitus
0.97Well supported

Genetic evidence dominant · Open Targets 0.61

Obesity disorder
0.97Well supported

Genetic evidence dominant · Open Targets 0.69

Hypertension
0.96Well supported

Genetic evidence dominant · Open Targets 0.59

Heart Failure
0.94Well supported

Genetic evidence dominant · Open Targets 0.58

View evidence synthesis (5)
Diabetes Mellitus, Type 2Well supported
0.98
agreement 0.841.00
Genetic87%Literature13%

Open Targets aggregate 0.62 · 2 independent evidence families

Diabetes MellitusWell supported
0.97
agreement 0.831.00
Genetic88%Literature12%

Open Targets aggregate 0.61 · 2 independent evidence families

Obesity disorderWell supported
0.97
agreement 0.831.00
Genetic87%Literature13%Genetic literaturedup

Open Targets aggregate 0.69 · 2 independent evidence families · 1 not counted as duplicate

HypertensionWell supported
0.96
agreement 0.821.00
Genetic94%Literature6%

Open Targets aggregate 0.59 · 2 independent evidence families

Heart FailureWell supported
0.94
agreement 0.811.00
Genetic96%Literature4%

Open Targets aggregate 0.58 · 2 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Obesity disorder0.69
Diabetes Mellitus, Type 20.62
Diabetes Mellitus0.61
Breast Neoplasms0.59
Hypertension0.59
Atrial Fibrillation0.59
Heart Failure0.58
Osteoarthritis0.58

Drug development

1 compounds recorded · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (1)
BISANTRENEPhase 2

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Advanced Clinical and Structure with Ligand support this modality.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)
SM · Advanced ClinicalSM · Structure with LigandSM · High-Quality LigandPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

leukopenia or neutropeniaClinPGxreduction in HDL-CClinPGxdrug toxicityClinPGxhypercholesteremiaClinPGxalcoholismClinPGxthiopurine-induced LeukopeniaClinPGx

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Research activity

3 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.